Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
561-580 of 1,694 trials

Acute Myeloid Leukemia: Decitabine and Venetoclax with ATRA

We are studying whether adding all-trans retinoic acid to a treatment regimen helps patients with acute myeloid leukemia who cannot receive standard chemotherapy. The goal is to see if this combination improves survival and treatment response.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesHematologyOncology

Penile Rehabilitation After Prostate Cancer Surgery: PEHAB II

We are studying two approaches to help men regain erections after nerve-sparing prostate surgery. The goal is to see which method leads to better sexual function and quality of life.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteUrology

Castration-Resistant Prostate Cancer: Darolutamide with Radiation Therapy

We are studying whether adding stereotactic radiation therapy to darolutamide helps patients with castration-resistant prostate cancer and a few metastases live longer without disease progression. We will also evaluate the treatment's safety and impact on quality of life.

Castration-Resistant Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Statin Intolerance: Personalized Treatment Study

We are exploring whether personalized treatment plans can help people who struggle with statin medications. The goal is to improve their cholesterol management while minimizing side effects.

High Cardiovascular RiskStatin Intolerance6-12 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Hip Replacement Surgery: Shorter Blood Thinner Duration

We are studying whether a shorter course of blood-thinning medication after hip replacement surgery is as effective as the standard duration in preventing blood clots. This trial aims to improve recovery and safety for patients.

Hip Osteoarthritis3-6 monthsConfirmation phase (III)Standard MedicinesHematologyOrthopedics and Traumatology

Lung Cancer Treatment: Entrectinib vs. Crizotinib

We are comparing the effectiveness and safety of two medications for patients with advanced non-small cell lung cancer that has a specific genetic change. This study includes individuals with and without brain metastases.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: Venetoclax Treatment Study

We are studying whether adding venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia live longer and achieve better treatment results. This trial compares venetoclax to a placebo to assess its impact on patient outcomes.

Acute Myeloid Leukemia6-12 monthsConfirmation phase (III)Standard MedicinesHematology

Moderate Acne: Oral Isotretinoin vs. Standard Care

We are comparing a new oral medication to standard treatments for moderate acne in patients with skin of color. Our goal is to see if this new approach improves acne severity and quality of life.

Acne6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesDermatology

Myasthenia Gravis: NMD670 Treatment Study

We are testing different doses of NMD670 in adults with Myasthenia Gravis to see if it improves muscle strength. This study will help us understand how effective the treatment is compared to a placebo.

Myasthenia Gravis≤3 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Multiple Sclerosis: Disodium Cromoglycate Treatment

We are studying whether oral disodium cromoglycate can help reduce fatigue and urinary problems in people with multiple sclerosis. The trial will also assess its safety and impact on quality of life.

Multiple SclerosisEfficacy phase (II)Standard MedicinesInternal MedicineNeurology

Atrial Fibrillation: Apixaban vs. Warfarin in Dialysis Patients

We are comparing the safety and effectiveness of apixaban and warfarin for patients with atrial fibrillation on peritoneal dialysis. The study focuses on bleeding risks and the prevention of strokes and other serious health events.

Chronic Ambulatory Peritoneal DialysisConfirmation phase (III)No PlaceboStandard MedicinesCardiologyNephrology

Advanced Breast and Gastric Cancers: Disitamab Vedotin with Tucatinib

We are studying a new combination of disitamab vedotin and tucatinib for patients with advanced breast and gastric cancers. The goal is to find the best dose and evaluate its safety and effectiveness.

HER2 Positive Breast CancerOesophageal AdenocarcinomaGastric Cancer1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Asciminib Roll-over Study for Leukemia Patients

We are examining the long-term safety of asciminib in patients with certain types of leukemia who have completed a previous study. This trial aims to see if continued treatment is beneficial for these patients.

Chronic Myeloid Leukaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Vertebral Osteomyelitis: Early Oral Antibiotics Study

We are investigating if switching to oral antibiotics after one week is as effective as continuing intravenous treatment for pyogenic vertebral osteomyelitis. This study will also assess safety, hospital stays, and quality of life for patients.

Pyogenic Vertebral Osteomyelitis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesOrthopedics and TraumatologyRheumatology

Membranous Nephropathy: Dapagliflozin Treatment Study

We are investigating how dapagliflozin affects immune activity and kidney function in patients with Membranous Nephropathy. This study may help us understand its potential benefits for managing this condition.

Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Myotonic Dystrophy Type I: Metformin Study

We are investigating whether metformin can improve muscle and overall function in patients with Myotonic Dystrophy Type I. The study will also assess the safety of metformin and its effects on quality of life.

Myotonic Dystrophy Type 1 (DM1)>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Inclusion Body Myositis: Ruxolitinib Treatment Study

We are investigating whether ruxolitinib can improve movement and muscle function in patients with Inclusion Body Myositis. The study also looks at safety and quality of life for participants.

Inclusion Body Myositis>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyRheumatology

Prostate Cancer: [225Ac]Ac-PSMA-R2 Treatment Study

We are studying a new treatment for men with advanced prostate cancer to see if it is safe and effective. This trial includes men who have been treated before and those who have not.

Advanced Prostate CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: Selpercatinib Access Program

We are providing access to selpercatinib for adults with locally advanced or metastatic solid tumors that have specific genetic changes. This program aims to help patients who may benefit from this targeted treatment.

Various Types of Cancer>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Hepatocellular Carcinoma: Durvalumab and Bevacizumab Study

We are studying whether the combination of durvalumab and bevacizumab can help prevent cancer recurrence in patients with hepatocellular carcinoma after surgery or ablation. This trial compares these treatments to a placebo to assess their effectiveness.

Early Stage Liver Cancer>2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteHepatologyOncology